Wood Laura S, Moldawer Nancy P, Lewis Colleen
Cleveland Clinic Foundation, Ohio.
Cedars-Sinai Medical Center.
Clin J Oncol Nurs. 2019 Jun 1;23(3):271-280. doi: 10.1188/19.CJON.271-280.
Immune checkpoint inhibitor (ICI) therapy is a fast-developing field within the spectrum of cancer care. ICIs are associated with distinctive immune-related adverse events (irAEs), reflecting their unique mechanisms of action.
Effective management of irAEs requires early recognition and prompt reporting of their signs and symptoms; appropriate patient education is critical to maximizing this opportunity.
A comprehensive literature search was conducted in the public domain concerning awareness, assessment, and management of irAEs associated with ICIs.
Educational resources should provide timely, consistent, and personalized information, using a variety of teaching strategies that consider individual patient needs. Patient education should be developed with interprofessional team input and regularly reviewed in response to emerging guidance. Key messages include timing of therapeutic response and corresponding irAEs, early identification of irAEs, and the unique ability of ICIs to influence immune responses after treatment discontinuation.
免疫检查点抑制剂（ICI）疗法是癌症治疗领域中一个快速发展的领域。ICI与独特的免疫相关不良事件（irAE）相关，反映了其独特的作用机制。
有效管理irAE需要早期识别并及时报告其体征和症状；适当的患者教育对于最大限度地利用这一机会至关重要。
在公共领域进行了一项关于与ICI相关的irAE的认识、评估和管理的全面文献检索。
教育资源应使用考虑个体患者需求的各种教学策略，提供及时、一致和个性化的信息。患者教育应在跨专业团队的参与下制定，并根据新出现的指南定期进行审查。关键信息包括治疗反应的时间和相应的irAE、irAE的早期识别，以及ICI在治疗中断后影响免疫反应的独特能力。
